{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-125384","form_type":"8-K","ticker":"OLMA","cik":"0001750284","company_name":"Olema Pharmaceuticals, Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.464056+00:00","generated_at":"2026-05-30T02:04:16.182765+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Olema Pharma Q3 net loss $34.6M; cash $214.8M; OP-3136 IND on track","bullets":["Q3 2024 net loss $34.6M vs $21.5M in Q3 2023; GAAP R&D $33.2M (up from $19.5M).","Cash, equivalents, marketable securities $214.8M as of Sep 30, 2024; no revenue reported.","OPERA-01 Phase 3 palazestrant monotherapy enrolling; top-line readout expected 2026.","IND submission for KAT6 inhibitor OP-3136 expected before year-end; Phase 1 start early 2025.","Updated Phase 2 palazestrant + ribociclib data to be presented at SABCS December 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-125384","json":"https://secwatch.observer/filing/0000950170-24-125384.json","markdown":"https://secwatch.observer/filing/0000950170-24-125384.md","text":"https://secwatch.observer/filing/0000950170-24-125384.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750284/000095017024125384/0000950170-24-125384-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750284/000095017024125384/olma-20241112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:04:16.182765+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}